Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETIC: Coagulation Factor Concentrates vs FFP in Trauma
NCT01545635Phase 3Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Mar 2012
- Primary completion
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Fibrinogen human and prothrombin complex concentrate, human in trauma-induced coagulopathy (TIC) (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Multiple Organ Failure at 24 hours. Started Mar 2012; status: terminated.
02
Drugs
Fibrinogen humanprothrombin complex concentrate, human
03
Conditions
trauma-induced coagulopathy (TIC)
Beyond the preview
Go deeper on NCT01545635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545635.